See us at AHA Scientific Sessions 2017 November 11-15 Anaheim
See us at the Quantitative Imaging Reading Room at RSNA 2017, November 27-December 1 Chicago
Medical imaging is among the most important innovations of our time, but modern healthcare asks more from it than ever before, Elucid Bioimaging develops products to answer this call…
Realizing the Power of Imaging in Medicine
Misclassification rates resulting in over- and under-diagnosis are too high in cardiology and oncology, driving costs. This uncertainty makes it even harder to measure change reliably, one of the requirements for the use of imaging in personalized medicine. Successive rounds of hardware innovations produce ever bigger data sets, ever richer – but which challenge unaided interpretation.
What would it look like to better align medical imaging to the goals of outcome-based reimbursement models needed by Accountable Care Organizations? To scale well to address the needs of integrated delivery networks?
Elucid Bioimaging addresses these needs using its patented, multi-modality, Computer-Aided Phenotyping (CAP) Platform, first in cardiology and oncology, with potential beyond.
Elucid Bioimaging, the pioneer of Computer-Aided Phenotyping (CAP)™ in medical imaging, is pleased to announce that the research edition of our software product, vascuCAP, is now available for purchase. vascuCAP Research Edition can aid researchers by providing a multifactorial, quantitative imaging biomarker panel of specific, biologically objective, and continuous-valued measurements such as distribution of lipid core and other determinants of lesion phenotype. It may be used to improve speed and efficiency in developing new therapeutics through use in trials by generation of readouts that can be used as markers of efficacy.
VascuCAP Clinical Release is now available for sale in the United States (K163071)
Elucid’s radiological image and annotation database/knowledgebase system, CAPbase, is also now available. CAPbase is an imaging study data management system that enables storage and representation of hierarchical study data over de-identified human and animal subjects as well as phantoms and synthetic data objects. A subset of features include the handling of multiple longitudinal encounters per subject, annotation of cases including demographics, medications, observations and outcomes, histopathological specimen annotations, and grouping of cases into cohorts. Additional capabilities include the tracking of technical performance data such as inter- and intra-reader statistics, collation of data according to user-selected search criteria, the handling of clinical and preclinical images as well as technical research data, and more functionality that goes beyond what you would expect to handle with a clinical PACS.
CAPgraph, also now available, is a progressive implementation of linked data and supporting toolset that enables results capture and data mining. CAPgraph enables straightforward case reporting, both previously defined as well as post-facto trend analyses, and inferential reasoning over user-defined cuts on multivariate data. It includes the capability to extract specific types/classes within a larger dataset for purposes of statistical analysis for surveillance or discovery research. Data mining with CAPgraph allows for deep dives into datasets by combining the imaging-based analysis of anatomic targets with other objective patient data, i.e. clinical chemistry and other blood biomarkers. CAPgraph may be used to evaluate technical performance factors in imaging studies, assess clinical performance such as effect size, examine clinical utility by means including outcome correlation, and elucidate causal relationships between proximal vs. distal markers to establish surrogacy or discover patterns in study populations.
lungCAP quantitatively and objectively analyzes the verifiable biophysical hallmarks predictive of malignancy. lungCAP processes low dose computed tomography images of the lung lesions to provide quantitative measurement, classification, and prediction of biological parameters with the potential to significantly improve the accuracy and cost effectiveness of lung cancer screening, and is particularly suited to some of the more challenging clinical presentations.
Customized Systems and Solutions
Elucid Bioimaging can customize your solution to fit your requirements
- Custom-designed CAP client software for other disease areas
- System Definition
- Systems Engineering
- System test and validation
Clinical Trial Services
Elucid provides clinical trial support from Phase I to Phase IV – from implementation of our CAP clients like vascuCAP to trial data management, analysis, and reporting
- Screen patient populations for trial entry
- Conduct longitudinal studies to establish the effectiveness of drug therapy, enabling new claims and extending patent protection.
- Exploratory endpoint studies for drugs aimed at atherosclerosis
- lungCAP or specialized CAP clients for other disease areas
- Distributed or centralized reading services
- Data management and reporting for any trial phase
Elucid provides direct analysis capability at its in-house data center for specific image studies or to characterize performance of biomarkers clients are working to develop or to utilize.
Inquiries may be made by contacting us either by phone or email
"Great things in science are never done by one person. They're done by a team of people."